Browsing Tag
motion sickness treatment
1 post
Vanda Pharmaceuticals (NASDAQ: VNDA) gains after FDA sets new December 5 date for tradipitant re-review
Vanda Pharmaceuticals moves closer to FDA approval for tradipitant in motion sickness while targeting the GLP-1 side effect market. Find out what’s next.